SIU School of Medicine, like medical schools around the country, interacts with the biomedical industry (pharmaceutical and medical device companies) and their representatives in many areas of mutual interest. As with any such relationships, it is incumbent on the School’s faculty, staff, and learners to be aware that conflicts of interest can arise. Medical schools and industry must be careful to maintain the appropriateness of their relationships to ensure that they respect the fundamental responsibilities that are at the heart of their respective missions.
To that end, SIU School of Medicine has developed industry relations policies. These policies were developed by the medical school’s twenty-three member Task Force on Industry Relations over an eighteen-month period, and were carefully reviewed and approved by the School’s Executive Committee. They are based on policy recommendations of the Association of American Medical Colleges and reflect emerging national norms on the subject. The medical school’s industry relations policies will go far in ensuring appropriate, productive relationships between industry and SIU’s medical school.
- Chapter: Site Access by Industry
- Chapter: Gifts and Samples from Industry
- Chapter: Continuing Medical Education and Industry
- Chapter: Industry-Provided Meals, Travel, and Lodging
- Chapter: Consulting Activities and External Professional Relationships
- Chapter: Honoraria from Industry
- Chapter: Other
- 1: Public Endorsements
- 2: Ghostwriting
- 3: Purchasing
- 4: Industry-Sponsored Scholarships and Other Educational Funds for Students and Residents/Fellows Not Employed by a Teaching Hospital
- 5: Industry-Sponsored Scholarships and Other Educational Funds for Residents/Fellows Employed by a Teaching Hospital
- Oversight and Compliance
Request for Approval of Educational Materials and Missions and/or Business Travel
Open Payments is a federal program, required by the Affordable Care Act, that collects information about the payments drug and device companies make to physicians and teaching hosptials. As such, the Centers for Medicare and Medicaid Service's (CMS) rule entitled, "Transparency Reports and Reporting of Physician Ownership or Investment Interests" or also known as the Physician Payments Sunshine Act, requires applicable manufacturers of drugs, devices, biologicals, or medical supplies to report to CMS on an annual basis certain payments or transfers of value made to physicians or teaching hospitals. It also requires manufacturers and group purchasing organizations to disclose physician ownership or investment interests.
The data are published annually on the CMS "Open Payments" website. Physicians and teaching hospitals have the opportunity to review and dispute the payments reported about them before the data is made publicly available.